The abstract is read at the publisher; the summary is JClub's.
CDKN2A/MTAP deletion (CMdel) occurs in 11.7% of NSCLC patients and defines a genomically distinct subset enriched for actionable drivers and worse outcomes on ICI/chemotherapy.
- Why it matters: The clinicogenomic context and treatment-outcome links for CMdel in NSCLC are not well established, limiting biomarker-guided therapeutic development.
- What they did: Using Tempus Lens paired DNA/RNA sequencing, the study analyzed 16,947 patients (primary) and 10,996 (validation), stratifying CMdel vs CM wild-type and assessing TTNT across first-line regimen groups.
- The result: CMdel tumors showed lower PD-L1, mutation burden, and immune infiltration, and TTNT was shorter for CMdel with ICI chemotherapy and chemotherapy, while IFNK-low marked immune-excluded subgroups with worse outcomes.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.